Exploratory Analysis Comparing Fosnetupitant Versus Fosaprepitant for Prevention of Highly Emetogenic Chemotherapy-Induced Nausea and Vomiting (CINV): A Randomized, Double-Blind, Phase 3 Study (CONSOLE)

Akito Hata, Tomohide Tamura(St. Luke's International Hospital), Morihito Okada(Hiroshima University), Toshiaki Saeki(Saitama International Medical Center), Naofumi Shinagawa(Hokkaido University), Masahiro Morise(Nagoya University), Shunichi Sugawara(Sendai Kousei Hospital), Masayuki Takeda(Kindai University), Kaoru Kubota(Nippon Medical School Hospital), Kohei Akiyoshi(Osaka City General Hospital), Yoshimasa Shiraishi(Kyushu University), Yasutaka Watanabe(Saitama Cancer Center), Naoki Inui(Hamamatsu University School of Medicine)
Oncology and Therapy
March 4, 2022
10.1007/s40487-022-00188-2
Cited by 17

Related Papers

Gefitinib or Chemotherapy for Non–Small-Cell Lung Cancer with Mutated EGFR
|New England Journal of Medicine|2010|5.6k
Pembrolizumab plus Chemotherapy for Squamous Non–Small-Cell Lung Cancer
|New England Journal of Medicine|2018|3.7k
Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial
|The Lancet|2019|3.4k
Adjuvant atezolizumab after adjuvant chemotherapy in resected stage IB–IIIA non-small-cell lung cancer (IMpower010): a randomised, multicentre, open-label, phase 3 trial
|The Lancet|2021|1.5k
Association of Immune-Related Adverse Events With Nivolumab Efficacy in Non–Small-Cell Lung Cancer
|JAMA Oncology|2017|1k